Ademetionine

Drug Profile

Ademetionine

Alternative Names: MSI-190; MSI-195; S-Adenosyl-L-Methionine; SAMe; Strada

Latest Information Update: 09 Jun 2017

Price : $50

At a glance

  • Originator MSI Methylation Sciences
  • Class Amino acids; Antidepressants; Nootropics
  • Mechanism of Action Beta adrenergic receptor modulators; Biogenic monoamine uptake modulators; Cytokine modulators; Muscarinic receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder

Most Recent Events

  • 09 Jun 2017 Ademetionine is still at phase II development stage for Major depressive disorder in USA (PO) (MSI Methylation Sciences website, June 2017)
  • 15 Dec 2016 Biomarkers information updated
  • 06 Sep 2016 MSI Methylation Sciences plans a pivotal phase III programme for Major depressive disorder (Adjunctive treatment) in USA, European Union and Japan (MSI Methylation Sciences pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top